In a report released on April 24, Shane Storey from Wilsons downgraded Next Science Ltd (NXSCF – Research Report) to a Hold, with a price target of A$0.70. The company’s shares closed yesterday at $0.48.
Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals Ltd., CSL, and Impedimed Limited. According to TipRanks, Storey has an average return of 14.8% and a 67.24% success rate on recommended stocks.
Next Science Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $0.52.
See Insiders’ Hot Stocks on TipRanks >>
NXSCF market cap is currently $102M and has a P/E ratio of -8.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Next Science Ltd is an Australia based company formed to commercialise and develop its Xbio technology, which is a non-toxic technology with efficacy in eradicating both biofilm based and free-floating bacteria. The company’s products includes SurgX Sterile wound Gel, Bactisure Surgical Lavage and Blast X Wound Gel.
